Orthocell (ASX: OCC) — Company Overview, News & Financial Data
Orthocell is a regenerative medicine company that develops and commercializes cell therapies and collagen-based medical devices for tissue repair and regeneration.
Orthocell
Orthocell is a regenerative medicine company that develops and commercializes cell therapies and collagen-based medical devices for tissue repair and regeneration. The company produces biological solutions to address severe injuries to bones, tendons, and peripheral nerves, aiming to restore functional mobility in patients. Its product pipeline and commercial portfolio include resorbable collagen nerve wraps, dental barrier membranes for bone regeneration, and personalised autologous cell therapies for tendon and cartilage repair. Headquartered in Murdoch, Western Australia, the business operates accredited therapeutic manufacturing facilities and distributes medical devices across global healthcare markets including Australia and North America.
Snapshot
Operations
Products and/or services of Orthocell
- Nerve Wrap Devices: Biocompatible and resorbable collagen nerve wraps engineered to support the repair and protection of peripheral nerves by providing compression-free shielding and an optimal microenvironment to facilitate natural neural tissue healing.
- Dental Regeneration Membranes: Collagen barrier membranes engineered for guided bone and tissue regeneration in dental applications, creating a protective matrix over surgical sites to facilitate localized structural bone and soft tissue restoration.
- Autologous Tendon Cell Therapies: Personalised cell-based therapies using autologous tenocyte implantation for the treatment of severe chronic tendinopathy and damaged tendons, designed to regenerate tendon tissue and restore joint function and physical mobility.
- Autologous Cartilage Cell Therapies: Personalised biological treatments using autologous chondrocyte implantation to repair articular cartilage defects in knee and ankle joints, offering targeted cellular tissue restoration for damaged structural joint surfaces.
- Medical Device and Cell Manufacturing: Dedicated production operations certified to ISO 13485 quality standards and licensed by the Australian Therapeutic Goods Administration to manufacture collagen-based biological medical devices and human cell therapy products.
- Global Product Distribution Network: International commercialization operations supplying regenerative collagen devices and biological cell therapies across key healthcare jurisdictions, including Australia, the United States, Canada, the United Kingdom, and the European Union.
Orthocell executive team
- Paul Frederick AndersonCEO, MD & Executive Director
- Jim PiperChief Financial Officer
- Ming Hao ZhengChief Scientific Officer and Member of Medical & Scientific Advisory Board
- Tony MacintyreChief Technical Operations Officer
- Adam WoodChief Commercial Officer
- Peter Gordon WebseCompany Secretary
- John WalkerVice President of Sales USA
Latest news about Orthocell
Orthocell posts record $279,000 U.S. sales in October
AustraliaOrthocell completes first US military surgical case
AustraliaOrthocell secures major US military hospital approval
AustraliaOrthocell appoints exclusive UK distributor for Remplir
AustraliaOrthocell hits 100-unit milestone for Remplir in US
Australia
Recent announcements
What Orthocell (OCC) has told the market, newest first.
- Remplir Shows Excellent Early Prostatectomy ResultsPrice sensitive
- Letter to Shareholders, Notice of AGM & Proxy Form
- Change of Auditor
Key financials
Reported results for Orthocell, in AUD.
- Market cap
- 145.7M
- Revenue (TTM)
- 11.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- -122.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 11.4M | -18.4M | -13.9M | |
| 7.6M | -14M | -8.6M | |
| 5.3M | -11.7M | -7.2M | |
| 4.2M | -10.3M | -6.2M |